Company profile for Amarna Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene & immune-therapies. SVac is safe, non-immunogenic & vector particles can be produced cost effectively in our SuperVero packaging cell line. Based on its unique properties SVac is ideally suited for developing next generation effective gene & immune-ther...
Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene & immune-therapies. SVac is safe, non-immunogenic & vector particles can be produced cost effectively in our SuperVero packaging cell line. Based on its unique properties SVac is ideally suited for developing next generation effective gene & immune-therapies. In order to realize our ambition to become the leading global gene therapy company we formed a worldwide consortium of key players in the virology, oncology, neurology, immunology, ophthalmology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Leiden Bioscience Park J.H. Oortweg 21 2333 CH Leiden
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/07/08/3111837/0/en/Amarna-Therapeutics-and-NorthX-Biologics-Finalize-Agreement-to-Advance-Nimvec-AM510-Gene-Therapy-Toward-Clinical-Trials-for-Type-1-Diabetes.html

GLOBENEWSWIRE
08 Jul 2025

https://www.globenewswire.com/news-release/2024/12/11/2995467/0/en/Phenocell-and-Amarna-Therapeutics-Awarded-Eurostars-Grant-to-Assess-a-Gene-Therapy-for-Dry-AMD-using-a-novel-3-dimensional-iPSC-derived-Retinal-Model-of-the-Disease.html

GLOBENEWSWIRE
11 Dec 2024

https://www.globenewswire.com/news-release/2024/12/03/2991067/0/en/Amarna-Therapeutics-Partners-with-NorthX-Biologics-to-Advance-Nimvec-AM510-Gene-Therapy-Development.html

GLOBENEWSWIRE
03 Dec 2024

https://www.globenewswire.com/news-release/2024/08/27/2936019/0/en/Amarna-Therapeutics-Receives-Constructive-Feedback-from-FDA-INTERACT-Meeting-for-AM510-Gene-Therapy-Development-Targeting-Type-1-Diabetes.html

GLOBENEWSWIRE
27 Aug 2024

https://www.globenewswire.com/news-release/2024/06/17/2899442/0/en/Amarna-Therapeutics-announces-formation-of-Scientific-Advisory-Board-to-support-advancement-of-groundbreaking-Nimvec-AM510-gene-therapy-against-Type-1-Diabetes.html

GLOBENEWSWIRE
17 Jun 2024

https://www.globenewswire.com/news-release/2024/04/19/2866008/0/en/Amarna-Therapeutics-announces-appointment-of-Aurelia-Caparr%C3%B3s-as-new-Chief-Business-Officer.html

GLOBENEWSWIRE
19 Apr 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty